文献速递艾滋病与性传播感染病毒性肝炎

法国HIV-HCV合并感染流行病学变化:微消除与否?2012-2018

Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012-2018.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该研究基于法国Dat'AIDS前瞻性队列2012-2018年数据,回顾分析50 861例已知HCV状态的HIV感染者。结果显示HCV患病率从15.4%降至13.5%,但MSM新发HCV感染增加,病毒血症比例从67.0%降至8.9%,MSM成为2018年主要病毒血症群体。

要点

  • HIV-HCV合并感染总体患病率下降,但MSM新发HCV感染增加
  • 病毒血症患者比例大幅下降,MSM成为2018年主要病毒血症群体
  • DAA治疗 uptake 增加,MSM急性期治疗占2018年治疗30.0%

核心结论

  • 2012-2018年法国HIV感染者HCV流行病学发生重大转变,2018年MSM成为HCV传播主要群体。

研究设计与样本

  • 回顾性分析法国Dat'AIDS前瞻性队列2012-2018年数据,纳入50 861例已知HCV状态的HIV感染者。

主要发现

  • HCV患病率从15.4%降至13.5%,新发HIV病例中MSM的HCV患病率从1.9%升至3.5%,其他组稳定。
  • MSM新发HCV发病率从0.36/100人年升至1.25/100人年。
  • 病毒血症患者比例从67.0%降至8.9%,2018年MSM占病毒血症患者37.9%,其中新近感染占59.2%。
  • DAA治疗 uptake 从11.4%升至61.5%,2018年MSM治疗启动占41.2%,高于静脉吸毒者35.6%。

临床怎么用

  • 应加强MSM人群HCV筛查和急性期治疗,以推进HCV微消除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The arrival of highly effective, well-tolerated, direct-acting antiviral agents (DAA) led to a dramatic decrease in hepatitis C virus (HCV) prevalence. Human immunodeficiency virus (HIV)-HCV-coinfected patients are deemed a priority population for HCV elimination, while a rise in recently acquired HCV infections in men who have sex with men (MSM) has been described. We describe the variations in HIV-HCV epidemiology in the French Dat'AIDS cohort. METHODS: This was a retrospective analysis of a prospective cohort of persons living with HIV (PLWH) from 2012 to 2018. We determined HCV prevalence, HCV incidence, proportion of viremic patients, treatment uptake, and mortality rate in the full cohort and by HIV risk factors. RESULTS: From 2012 to 2018, 50 861 PLWH with a known HCV status were followed up. During the period, HCV prevalence decreased from 15.4% to 13.5%. HCV prevalence among new HIV cases increased from 1.9% to 3.5% in MSM but remained stable in other groups. Recently acquired HCV incidence increased from 0.36/100 person-years to 1.25/100 person-years in MSM. The proportion of viremic patients decreased from 67.0% to 8.9%. MSM became the first group of viremic patients in 2018 (37.9%). Recently acquired hepatitis represented 59.2% of viremic MSM in 2018. DAA treatment uptake increased from 11.4% to 61.5%. More treatments were initiated in MSM in 2018 (41.2%) than in intravenous drug users (35.6%). In MSM, treatment at the acute phase represented 30.0% of treatments in 2018. CONCLUSIONS: A major shift in HCV epidemiology was observed in PLWH in France from 2012 to 2018, leading to a unique situation in which the major group of HCV transmission in 2018 was MSM. Clinical Trials Registration. NCT02898987.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Cotte L, Hocqueloux L, Lefebvre M, et al. Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012-2018. Clin Infect Dis. 2021. PMID: 33400777. doi:10.1093/cid/ciaa1940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。